|
ISRCTN
|
ISRCTN20141297
|
|
ClinicalTrials.gov identifier
|
NCT00632983
|
|
Public title
|
The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer
|
|
Scientific title
|
|
|
Acronym
|
ProtecT
|
|
Serial number at source
|
HTA 96/20/99
|
|
Study hypothesis
|
The overall aim is to evaluate the effectiveness, cost-effectiveness and acceptability of treatments for men with localised prostate cancer within the context of a pragmatic randomised controlled trial. This will compare 3 treatments (active monitoring, radical prostatectomy and radical radiotherapy). Specific objectives are as follows:
1. To assess survival at 5, 10 years and 15 years following treatment
2. To investigate a number of short and medium-term outcomes, including: disease progression (biochemical and clinical), treatment complications, lower urinary tract symptoms, psychosocial impact of case-finding and treatment, including generic health status, quality of life and sexual function
3. To estimate the resource use and costs of case-finding, treatment and follow-up, and to compare costs and outcomes of treatment in terms of survival and health related quality of life.
Details of this study can also be found at: http://www.hta.ac.uk/1230
Please note that, as of 11 January 2008, the anticipated end date of this trial has been updated from 1 June 2006 to 31 December 2013.
Please note that as of 28/04/10 the Principal Investigator of this trial has moved from the University of Sheffield to the University Oxford. The sponsor and contact details below have been updated accordingly.
|
|
Ethics approval
|
Trent Multi-centre Research Ethics Committee (Trent MREC), approved on 21/06/2001 (ref: 01/4/025)
|
|
Study design
|
Randomised controlled trial
|
|
Countries of recruitment
|
United Kingdom
|
|
Disease/condition/study domain
|
Prostate cancer
|
|
Participants - inclusion criteria
|
Men aged 50-69 years from the community, localised prostate cancer for eligibility for randomisation
|
|
Participants - exclusion criteria
|
Not provided at time of registration.
|
|
Anticipated start date
|
01/06/2001
|
|
Anticipated end date
|
31/12/2013
|
|
Status of trial
|
Ongoing |
|
Patient information material
|
Patient information can be found at: http://www.epi.bris.ac.uk/protect/takingpart/takingpart.htm
|
|
Target number of participants
|
230,000
|
|
Interventions
|
1. Radical prostatectomy
2. Radical radiotherapy
3. Active monitoring of prostate specific antigen (PSA) levels
See details of ISRCTN08435261: ProtecT feasibility on http://www.controlled-trials.com/ISRCTN08435261 and details of ISRCTN92187251: The CAP (Comparison Arm for ProtecT) study on http://www.controlled-trials.com/ISRCTN92187251
|
|
Primary outcome measure(s)
|
1. Disease progression (biochemical and clinical)
2. Treatment complications
3. Lower urinary tract symptoms
4. Psychosocial impact of case-finding and treatment including generic health status, quality of life and sexual function
|
|
Secondary outcome measure(s)
|
Not provided at time of registration.
|
|
Sources of funding
|
NIHR Health Technology Assessment Programme - HTA (UK)
|
|
Trial website
|
http://www.epi.bris.ac.uk/protect/
|
|
Publications
|
1. 2006 results in http://www.ncbi.nlm.nih.gov/pubmed/16978272
2. 2007 results in http://www.ncbi.nlm.nih.gov/pubmed/18006969
3. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20372151
|
|
Contact name
|
Prof
F C
Hamdy
|
|
Address
|
Professor of Surgery and Urology
Head of Nuffield Department of Surgery
Faculty of Medical Science
University of Oxford
John Radcliffe Hospital
|
|
City/town
|
Oxford
|
|
Zip/Postcode
|
OX3 9DU
|
|
Country
|
United Kingdom
|
|
Email
|
Freddie.hamdy@nds.ox.ac.uk
|
|
Sponsor
|
University of Oxford (UK)
|
|
Address
|
Faculty of Medical Science
John Radcliffe Hospital
|
|
City/town
|
Oxford
|
|
Zip/Postcode
|
OX3 9DU
|
|
Country
|
United Kingdom
|
|
Sponsor website:
|
http://www.ox.ac.uk
|
|
Date applied
|
14/10/2002
|
|
Last edited
|
11/06/2010
|
|
Date ISRCTN assigned
|
14/10/2002
|
